Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 9.26%

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) has an Asset Resilience Ratio of 9.26% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Daishin Balance No.6 Special Purpose Acq balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩16.46 Billion
≈ $11.16 Million USD Cash + Short-term Investments

Total Assets

₩177.78 Billion
≈ $120.48 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Daishin Balance No.6 Special Purpose Acq for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 307750 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩16.46 Billion 9.26%
Total Liquid Assets ₩16.46 Billion 9.26%

Asset Resilience Insights

  • Limited Liquidity: Daishin Balance No.6 Special Purpose Acquisition Co. Ltd maintains only 9.26% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 7.18%
CSPC Pharmaceutical Group Limited
F:CVG
Drug Manufacturers - General 4.64%
Aurora Optoelectronics Co Ltd
SHG:600666
Drug Manufacturers - General 5.89%
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
Drug Manufacturers - General 6.44%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 10.10%
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 7.18%
Merck & Company Inc
NYSE:MRK
Drug Manufacturers - General 14.06%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%

Annual Asset Resilience Ratio for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 22.05% ₩46.81 Billion
≈ $31.72 Million
₩212.27 Billion
≈ $143.85 Million
-6.74pp
2023-12-31 28.79% ₩64.82 Billion
≈ $43.93 Million
₩225.10 Billion
≈ $152.55 Million
-19.63pp
2022-12-31 48.43% ₩94.96 Billion
≈ $64.36 Million
₩196.10 Billion
≈ $132.89 Million
+29.58pp
2021-12-31 18.84% ₩20.16 Billion
≈ $13.66 Million
₩106.99 Billion
≈ $72.50 Million
+18.53pp
2020-12-31 0.31% ₩180.00 Million
≈ $121.98K
₩57.80 Billion
≈ $39.17 Million
--
pp = percentage points

About Daishin Balance No.6 Special Purpose Acquisition Co. Ltd

KQ:307750 Korea Drug Manufacturers - General
Market Cap
$132.95 Million
₩196.19 Billion KRW
Market Cap Rank
#18096 Global
#891 in Korea
Share Price
₩3910.00
Change (1 day)
-2.25%
52-Week Range
₩3040.00 - ₩5540.00
All Time High
₩22045.88
About

KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more